Menu Search
Equities

Labcorp Holdings Inc

N6B:STU

Labcorp Holdings Inc

Actions
  • Price (EUR)218.00
  • Today's Change-3.00 / -1.36%
  • Shares traded0.00
  • 1 Year change+12.95%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and advanced science to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is also focused on clinical diagnostics and reproductive and women's health in the United States outside of New York and New Jersey.

  • Revenue in USD (TTM)12.71bn
  • Net income in USD435.50m
  • Incorporated2024
  • Employees67.00k
  • Location
    Labcorp Holdings Inc358 S Main StBURLINGTON 27215United StatesUSA
  • Phone+1 (336) 229-1127
  • Fax+1 (302) 636-5454
  • Websitehttps://www.labcorp.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.